Pain

Pain management company, U.S. FDA discuss injectable non-narcotic analgesic

Published in Medical Letter on the CDC and FDA, September 12th, 2004

TheraQuest Biosciences, a pain management company, announced it had held a pre-investigational new drug application (IND) conference with the United States Food and Drug Administration (FDA) for its injectable non-narcotic (nonopioid) analgesic, TQ-1011, for the management of moderate to severe acute pain.

The U.S.FDA's pre-IND meeting programs are designed to provide sponsors with advance guidance and input on drug development programs. TheraQuest has also completed consultations on TQ-1011 with the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) and the Canadian Therapeutic Products Directorate (TPD).

The treatment of post-surgical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-09-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry